35. Philip H. Abelson, "Pharmaceuticals Based on Biotechnology," Science, 273, 719 (9 August 1996).
This is an analysis of a) the increase in medicines designed to treat hitherto refractory diseases, b) the development of these new medicines by U.S. biotechnology companies, and c) increasing alliances between the small biotechnology companies who possess interesting proprietary assets and the pharmaceutical giants whose conventional research programs were not producing enough new medicines. They can finance the huge costs required for clinical tests prior to licensure by the F.D.A.; the biotechnology companies provide the ideas.
Home Fall 96 Full Screen
Fall 96 - Resources: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36The TEACHERS CLEARINGHOUSE FOR SCIENCE AND SOCIETY EDUCATION